Medicamen Biotech Ltd. | Small-cap | Healthcare
₹414.85
-1.60%
| Medicamen Biotech Stock Comparison:
No comparison data available
Overview Income Statement Balance Sheet Cash Flow Key Ratios

Financial Overview

Latest Annual: 2025

Income Metrics

Revenue 1.6B
Gross Profit 779.3M 47.94%
Operating Income 67.9M 4.18%
Net Income 65.6M 4.03%
EPS (Diluted) ₹5.16

Balance Sheet Metrics

Total Assets 3.0B
Total Liabilities 841.0M
Shareholders Equity 2.1B
Debt to Equity 0.40

Cash Flow Metrics

Operating Cash Flow -166.0M
Free Cash Flow -92.7M

Revenue & Profitability Trend

Medicamen Biotech Income Statement From 2021 to 2025

Metric 2025 2024 2023 2022 2021
Revenue 1.6B 1.8B 1.4B 1.2B 1.1B
Cost of Goods Sold 846.2M 926.0M 859.9M 674.6M 792.0M
Gross Profit 779.3M 867.1M 548.8M 479.9M 335.2M
Operating Expenses 322.0M 344.0M 85.7M 81.8M 45.4M
Operating Income 67.9M 151.5M 188.9M 190.0M 171.5M
Pre-tax Income 98.8M 130.8M 170.4M 180.9M 163.9M
Income Tax 33.2M 35.8M 23.2M 32.0M 42.6M
Net Income 65.6M 94.9M 147.3M 149.0M 121.3M
EPS (Diluted) ₹5.16 ₹8.63 ₹11.73 ₹12.19 ₹9.93

Income Statement Trend

Medicamen Biotech Balance Sheet From 2021 to 2025

Metric 2025 2024 2023 2022 2021
Assets
Current Assets 1.6B 1.6B 1.6B 1.2B 960.3M
Non-Current Assets 1.3B 1.3B 1.2B 1.0B 976.9M
Total Assets 3.0B 2.9B 2.8B 2.3B 1.9B
Liabilities
Current Liabilities 781.7M 845.6M 825.7M 726.9M 532.7M
Non-Current Liabilities 59.4M 30.1M 25.3M 65.3M 75.6M
Total Liabilities 841.0M 875.7M 851.0M 792.2M 608.3M
Equity
Total Shareholders Equity 2.1B 2.1B 1.9B 1.5B 1.3B

Balance Sheet Composition

Medicamen Biotech Cash Flow Statement From 2021 to 2025

Metric 2025 2024 2023 2022 2021
Operating Activities
Net Income 65.5M 94.9M 147.3M 149.0M 121.3M
Operating Cash Flow -166.0M -21.9M -119.4M -89.3M 155.5M
Investing Activities
Capital Expenditures -20.7M -62.9M -66.0M -86.1M -179.7M
Investing Cash Flow -23.8M -62.9M -66.0M -86.1M -179.7M
Financing Activities
Dividends Paid -12.7M -12.7M -12.7M -12.2M -6.1M
Financing Cash Flow 11.7M 107.1M 324.6M 57.0M 69.0M
Free Cash Flow -92.7M -130.3M -128.9M -45.0M -51.9M

Cash Flow Trend

Medicamen Biotech Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) 78.16
Price to Book 2.41
Price to Sales 3.42
PEG Ratio -1.94

Profitability Ratios

Profit Margin 4.37%
Operating Margin -7.05%
Return on Equity 3.12%
Return on Assets 1.44%

Financial Health

Current Ratio 2.10
Debt to Equity 15.63
Beta 1.03

Per Share Data

EPS (TTM) ₹5.17
Book Value per Share ₹167.35
Revenue per Share ₹127.84

Financial data is updated regularly. All figures are in the company's reporting currency.